Table 2. Parameters with established importance for assessing disease severity, stability and prognosis in pulmonary arterial hypertension
Better prognosisDeterminants of prognosisWorse prognosis
NoClinical evidence of right ventricle failureYes
SlowRate of progression of symptomsRapid
NoSyncopeYes
I, IINYHA/WHO FCIV
Longer (>500 m)#6MWTShorter (<300 m)
Peak O2 consumption >15 mL·min−1·kg−1Cardio-pulmonary exercise testingPeak O2 consumption <12 mL·min−1·kg−1
Normal or near normalBNP/NT-proBNP plasma levelsVery elevated and rising
No pericardial effusion TAPSE >2.0 cmEchocardiographic findingsPericardial effusion TAPSE <1.5 cm
Pra <8 mmHg and CI ≥2.5 L·min−1·m−2HaemodynamicsPra >15 mmHg or CI ≤2.0 L·min−1·m−2
  • NYHA/WHO FC: New York Heart Association/World Health Organization functional class; 6MWT: 6-min walk test; BNP: brain natriuretic peptide; NT-proBNP: N-terminal pro-B-type natriuretic peptide; TAPSE: tricuspid annular plane systolic excursion; Pra: right atrial pressure; CI: cardiac index. #: depending on age; : TAPSE and pericardial effusion have been selected as they can be measured in the majority of patients. Reproduced from [13] with permission from the publisher.